In CRC, genistein can inhibit colon cancer cell migration by reversing EMT through inhibition of the Notch1/NF-κB/slug/E-cadherin pathway (179), suggesting its potential as an antimetabolite for colon cancer. Here, NFKB1 is linked to malignant colon neoplasm.